Mesoblast (MESO) Goodwill & Intangibles (2015 - 2026)
Mesoblast (MESO) posted Goodwill & Intangibles of $568.8 million for Q4 2025, down 0.53% sequentially from $571.8 million in Q2 2025, and down 1.06% YoY from $574.9 million in Q4 2024.
Analysis
Mesoblast (MESO) Goodwill & Intangibles (2015 - 2026) Analysis & Trends
Mesoblast has reported Goodwill & Intangibles for 11 years, with the latest figure at $568.8 million in Q4 2025.
- Quarterly Goodwill & Intangibles fell 1.06% year-over-year to $568.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $568.8 million (down 1.06% YoY) and the FY2025 annual result came in at $571.8 million, down 0.68% from the prior year.
- Goodwill & Intangibles retreated to $568.8 million in Q4 2025 per MESO's latest filing, from $571.8 million in the prior quarter.
- Over five years, Goodwill & Intangibles peaked at $698.9 million in Q2 2021 and troughed at $568.8 million in Q4 2025.
- A 5-year average of $593.1 million and a median of $578.3 million in 2022 frame the typical range for Goodwill & Intangibles.
- The sharpest annual moves came in 2021 and 2023: Goodwill & Intangibles grew 20.18% in 2021, then fell 16.9% in 2023.
- Over 5 years, Goodwill & Intangibles stood at $579.8 million in 2021, then fell by 0.33% to $577.9 million in 2022, then slipped by 0.23% to $576.6 million in 2023, then decreased by 0.29% to $574.9 million in 2024, then fell by 1.06% to $568.8 million in 2025.
- According to Business Quant data, Goodwill & Intangibles over the past three periods registered $568.8 million, $571.8 million, and $574.9 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Mesoblast | 2.24 Bn | 2.14 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 566.37 Mn |
| Dec 31, 2025 | 568.80 Mn |
| Jun 30, 2025 | 571.83 Mn |
| Dec 31, 2024 | 574.88 Mn |
| Jun 30, 2024 | 575.74 Mn |
| Dec 31, 2023 | 576.56 Mn |
| Jun 30, 2023 | 577.18 Mn |
| Mar 31, 2023 | 577.53 Mn |
| Dec 31, 2022 | 577.90 Mn |
| Sep 30, 2022 | 578.28 Mn |
| Jun 30, 2022 | 578.65 Mn |
| Mar 31, 2022 | 578.95 Mn |
| Dec 31, 2021 | 579.84 Mn |
| Sep 30, 2021 | 580.18 Mn |
| Jun 30, 2021 | 580.55 Mn |
| Mar 31, 2021 | 580.94 Mn |
| Dec 31, 2020 | 581.33 Mn |
| Sep 30, 2020 | 581.22 Mn |
| Jun 30, 2020 | 581.60 Mn |
| Mar 31, 2020 | 581.94 Mn |